UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC

European journal of cancer (1990), 2015-09, Vol.51, p.S625-S625

2015

Volltextzugriff (PDF)

Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse

International journal of infectious diseases, 2010-06, Vol.14 (6), p.e518-e521

2010

Volltextzugriff (PDF)

MA10.03 A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S133

2023

Volltextzugriff (PDF)

P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S271

2023

Volltextzugriff (PDF)

P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S577-S577

2021

Volltextzugriff (PDF)

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S309-S310

2023

Volltextzugriff (PDF)

16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S49-S50

2023

Volltextzugriff (PDF)

102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

ESMO open, 2024-03, Vol.9, p.102681, Article 102681

2024

Volltextzugriff (PDF)

P2.09-03 Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S331

2023

Volltextzugriff (PDF)

PD2.05 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1172-S1172

2019

Volltextzugriff (PDF)

OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1133-S1134

2019

Volltextzugriff (PDF)

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

ESMO open, 2022-10, Vol.7 (5), p.100572-100572, Article 100572

2022

Volltextzugriff (PDF)

43O A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors

ESMO open, 2024-02, Vol.9, p.102272, Article 102272

2024

Volltextzugriff (PDF)

12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial

ESMO open, 2024-03, Vol.9, p.102591, Article 102591

2024

Volltextzugriff (PDF)

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

ESMO open, 2022-06, Vol.7 (3), p.100507-100507, Article 100507

2022

Volltextzugriff (PDF)

OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1127-S1127

2019

Volltextzugriff (PDF)

O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1153-S1154

2019

Volltextzugriff (PDF)

197 POSTER Pathway determinants of 5-fluorouracil activity

European journal of cancer supplements, 2008, Vol.6 (12), p.62-63

2008

Volltextzugriff (PDF)

Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequencies?

The pharmacogenomics journal, 2013-10, Vol.13 (5), p.423-429

2013

Volltextzugriff (PDF)

Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer

Cancer imaging, 2012-05, Vol.12 (1), p.212-224

2012

Volltextzugriff (PDF)

Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer

Cancer imaging, 2012, Vol.12 (1), p.212-224

2012

Volltextzugriff (PDF)

Effects of rapeseed residue on lead and cadmium availability and uptake by rice plants in heavy metal contaminated paddy soil

Chemosphere (Oxford), 2011-10, Vol.85 (4), p.677-682

2011

Volltextzugriff (PDF)

Soil pollution assessment and identification of hyperaccumulating plants in chromated copper arsenate (CCA) contaminated sites, Korea

Chemosphere (Oxford), 2012-05, Vol.87 (8), p.872-878

2012

Volltextzugriff (PDF)

Eggshell and coral wastes as low cost sorbents for the removal of Pb2+, Cd2+ and Cu2+ from aqueous solutions

Journal of Industrial and Engineering Chemistry, 2012, 18(1), , pp.198-204

2012

Volltextzugriff (PDF)

Improving inpatient assessment of nutritional status using the Malnutrition Universal Screening Tool (MUST)

Proceedings of the Nutrition Society, 2022, Vol.81 (OCE3), Article E79

2022

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC

Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse

MA10.03 A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC)

P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR

P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial

102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

P2.09-03 Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis

PD2.05 Overall Survival in Pts with EGFRm+ NSCLC Receiving Sequential Afatinib and Osimertinib: Updated Analysis of the GioTag Study

OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

43O A dose-escalation study of TNO155 (TN) in combination with spartalizumab (SPA) or ribociclib (RIB) in adults with advanced solid tumors

12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer

O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer

197 POSTER Pathway determinants of 5-fluorouracil activity

Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequencies?

Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer

Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer

Effects of rapeseed residue on lead and cadmium availability and uptake by rice plants in heavy metal contaminated paddy soil

Soil pollution assessment and identification of hyperaccumulating plants in chromated copper arsenate (CCA) contaminated sites, Korea

Eggshell and coral wastes as low cost sorbents for the removal of Pb2+, Cd2+ and Cu2+ from aqueous solutions

Improving inpatient assessment of nutritional status using the Malnutrition Universal Screening Tool (MUST)

Aktive Filter

Suchergebnisse filtern